Runx1 protects against the pathological progression of osteoarthritis

• 作者: Chenchen Zhou Yujia Cui Yueyi Yang Daimo Guo Demao Zhang Yi Fan Xiaobing Li Jing Zou Jing Xie
• 来源期刊: 骨研究（英文版）
• 年，卷（期）: 2021,（4）
• 所属期刊栏目: ORIGINAL ARTICLES
• 页码范围: 618-629
• 页数: 12页
• 语种: 英文

摘要

INTRODUCTION Runt-related transcription factor-1 (Runx1), which is also known as core-binding factor α 2 or acute myeloid leukemia 1 (AML1), is known for its vital role in hematopoiesis and blood malignancies.1 In humans, the RUNX1 gene is one of the most common targets of genetic alterations in acute leukemia.2 In newborn mice, conven-tional knockout of Runx1 leads to the loss of hematopoietic capacity, and individuals cannot survive the early embryonic stage.3 In adult mice, conditional knockout (CKO) of Runx1 in the hematopoietic lineage directly causes myeloid malignancies, such as myelodysplastic syndrome, myeloproliferative neoplasm-like disease, and acute myeloid leukemia (AML).